[go: up one dir, main page]

MXPA05009103A - Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios. - Google Patents

Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.

Info

Publication number
MXPA05009103A
MXPA05009103A MXPA05009103A MXPA05009103A MXPA05009103A MX PA05009103 A MXPA05009103 A MX PA05009103A MX PA05009103 A MXPA05009103 A MX PA05009103A MX PA05009103 A MXPA05009103 A MX PA05009103A MX PA05009103 A MXPA05009103 A MX PA05009103A
Authority
MX
Mexico
Prior art keywords
proliferative
hyper
angiogenesis
disorders
perhydrotriazapine
Prior art date
Application number
MXPA05009103A
Other languages
English (en)
Inventor
Gan Wang
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MXPA05009103A publication Critical patent/MXPA05009103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Esta invencion se relaciona con diaril ureas novedosas, las composiciones farmaceuticas que contienen estos compuestos y el uso de aquellos compuestos o composiciones para el tratamiento de trastornos hiper-proliferativos y por angiogenesis, como un agente unico o en combinacion con terapias citotoxicas.
MXPA05009103A 2003-02-28 2004-03-01 Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios. MXPA05009103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45032303P 2003-02-28 2003-02-28
PCT/US2004/006283 WO2004078746A2 (en) 2003-02-28 2004-03-01 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders

Publications (1)

Publication Number Publication Date
MXPA05009103A true MXPA05009103A (es) 2006-04-18

Family

ID=32962493

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009103A MXPA05009103A (es) 2003-02-28 2004-03-01 Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.

Country Status (10)

Country Link
EP (1) EP1599466B1 (es)
JP (2) JP4594925B2 (es)
CN (1) CN1839126A (es)
AT (1) ATE489379T1 (es)
CA (1) CA2516624C (es)
DE (1) DE602004030222D1 (es)
ES (1) ES2357288T3 (es)
MX (1) MXPA05009103A (es)
WO (1) WO2004078746A2 (es)
ZA (1) ZA200506861B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
ME00275B (me) 1999-01-13 2011-02-10 Bayer Corp ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
MXPA04007830A (es) 2002-02-11 2005-07-01 Bayer Pharmaceuticals Corp Arilureas como inhibidores de cinasa.
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
CN1839126A (zh) * 2003-02-28 2006-09-27 拜耳制药公司 用于治疗癌症和其它病症的新的氰基吡啶衍生物
PL1626714T3 (pl) 2003-05-20 2007-12-31 Bayer Healthcare Llc Diarylowe pochodne mocznika do schorzeń, w których pośredniczy PDGFR
US8637553B2 (en) * 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
AU2013200394B2 (en) * 2003-07-23 2015-07-09 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
WO2006094626A1 (en) 2005-03-07 2006-09-14 Bayer Healthcare Ag Pharmaceutical composition comprising an omega- carboxyaryl substituted diphenyl urea for the treatment of cancer
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
US8580798B2 (en) 2005-12-21 2013-11-12 Bayer Intellectual Property Gmbh Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
WO2008079629A2 (en) * 2006-12-21 2008-07-03 Boehringer Ingelheim International Gmbh Formulations with improved bioavailability
JP5885012B2 (ja) * 2007-01-19 2016-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
KR100961891B1 (ko) * 2008-02-01 2010-06-09 연세대학교 산학협력단 혈관신생 억제용 약제학적 조성물
JP2011525503A (ja) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全を処置するためのジアリールウレア
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
CA2738828A1 (en) 2008-10-02 2010-04-08 Respivert Limited P38 map kinase inhibitors
WO2010048304A2 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
CA2746354A1 (en) 2008-12-11 2010-06-17 Respivert Limited P38 map kinase inhibitors
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
NZ620174A (en) 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
MX2012007684A (es) 2009-12-30 2012-10-05 Avila Therapeutics Inc Modificacion covalente ligando dirigida de proteina.
CN102617458A (zh) * 2010-05-18 2012-08-01 张南 抗癌用化合物的制备方法
CN102319242A (zh) * 2011-10-13 2012-01-18 济南海乐医药技术开发有限公司 吲唑双芳基脲化合物作为蛋白激酶抑制剂的应用
KR102413704B1 (ko) 2014-02-14 2022-06-24 레스피버트 리미티드 항염증성 화합물로서의 방향족 헤테로사이클릭 화합물
EP3345894B1 (en) * 2015-09-02 2021-12-29 Chen, Kuenfeng Compound having protein tyrosine phosphatase shp-1 agonist activity
WO2018035346A1 (en) * 2016-08-17 2018-02-22 Ichan School Of Medicine At Mount Sinal Kinase inhibitor compounds, compositions, and methods of treating cancer
WO2019034176A1 (zh) * 2017-08-18 2019-02-21 四川百利药业有限责任公司 一种喜树碱-抗体偶联物
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
KR20220045954A (ko) 2019-07-11 2022-04-13 이스케이프 바이오, 인크. Lrrk2 억제제들로서의 인다졸들 및 아자인다졸들
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
HRP20231699T1 (hr) 2019-12-30 2024-05-10 Deciphera Pharmaceuticals, Llc Formulacije inhibitora amorfne kinaze i postupci njihove primjene
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1149085C (zh) * 1997-12-22 2004-05-12 拜尔有限公司 用取代杂环脲抑制raf激酶
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
JP2001106673A (ja) * 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
US6492393B1 (en) * 1999-11-16 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
SK12712002A3 (sk) * 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
CN1839126A (zh) * 2003-02-28 2006-09-27 拜耳制药公司 用于治疗癌症和其它病症的新的氰基吡啶衍生物

Also Published As

Publication number Publication date
JP2010229142A (ja) 2010-10-14
ZA200506861B (en) 2006-06-28
ATE489379T1 (de) 2010-12-15
CA2516624A1 (en) 2004-09-16
DE602004030222D1 (de) 2011-01-05
JP2006519182A (ja) 2006-08-24
ES2357288T3 (es) 2011-04-25
WO2004078746A3 (en) 2004-12-02
JP4594925B2 (ja) 2010-12-08
EP1599466A2 (en) 2005-11-30
EP1599466B1 (en) 2010-11-24
CN1839126A (zh) 2006-09-27
WO2004078746A2 (en) 2004-09-16
CA2516624C (en) 2013-05-14

Similar Documents

Publication Publication Date Title
MXPA05009103A (es) Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios.
TW200504053A (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2004078748A3 (en) Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
IL144144A0 (en) Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MXPA05013637A (es) Inhibidores gsk-3 y usos de los mismos.
EP1562897A4 (en) PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
IL145830A0 (en) Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1
CL2004000437A1 (es) Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UA92503C2 (ru) Соединения 5-(фенилизоксазолилэтокси)-триазол-3-ил-замещенного пиридина для лечения неврологических, психиатрических или болевых расстройств
MXPA04001500A (es) Compuestos que tienen un efecto sobre la glucocinasa.
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
SI1545537T1 (sl) Agonisti alfa-7 nikoninskega receptorja in statini v kombinaciji
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
AU9543601A (en) Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
BG105731A (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
WO2007075650A3 (en) Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders

Legal Events

Date Code Title Description
GB Transfer or rights